Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
The Efficacy of Dash Combined With Time-Restricted Feeding (16/8) on Metabolic Associated Fatty Liver Disease Management: A Randomized Controlled Trial Publisher Pubmed



Nilghaz M1 ; Sadeghi A2 ; Koochakpoor G3 ; Poustchi H4 ; Khodadadi N1 ; Narimani B1 ; Ghods M1 ; Shafiee M1 ; Shahparvari MR1 ; Hekmatdoost A1, 5
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Clinical Nutrition, School of Nutrition and Food Technology, National Nutrition and Food Technology Research Institute, Shahid Beheshti University of Medical Sciences, Tehran, Iran
  2. 2. Gastroenterology and Liver Diseases Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran
  3. 3. Maragheh University of Medical Sciences, Maragheh, Iran
  4. 4. Digestive Disease Research Institute, Tehran University of Medical Sciences, Tehran, Iran
  5. 5. Department of Clinical Nutrition and Dietetics, Faculty of Nutrition and Food Technology, Shahid Beheshti University of Medical Sciences, Tehran, Iran

Source: Scientific Reports Published:2025


Abstract

Recent studies have utilized time-restricted feeding (16/8) (TRF) and dietary approaches to stop hypertension separately to manage metabolic-associated fatty liver disease (MAFLD); however, the effectiveness of combining these two approaches has not been investigated. The objective of this study was to examine the impact of TRF in conjunction with a DASH diet on various factors related to MAFLD. A 12-week randomized controlled trial was conducted to assess the impact of TRF (16/8), along with a DASH diet, compared with a control diet based on standard meal distribution, in patients with MAFLD. An investigation was conducted to examine alterations in anthropometric indices, as well as liver parameters, serum metabolic indices, and an inflammatory marker. The TRF plus DASH diet reduced body mass index (p = 0.03), abdominal circumference (p = 0.005), controlled attenuation parameter (CAP) (p < 0.001), alanine aminotransferase (p = 0.039), and aspartate aminotransferase (0.047) compared to the control group. The levels of insulin and homeostasis model assessment of insulin resistance reduced in both groups significantly (P < 0.05). In MAFLD patients, TRF (16/8) in combination with a DASH diet is superior to a low-calorie diet in promoting obesity indices, and hepatic steatosis and fibrosis. Further long-term investigations are needed to draw definitive conclusions. © The Author(s) 2025.
Experts (# of related papers)
Other Related Docs
12. Advancing the Global Public Health Agenda for Nafld: A Consensus Statement, Nature Reviews Gastroenterology and Hepatology (2022)
28. Adherence to the Dash Diet and Risk of Breast Cancer, Clinical Breast Cancer (2022)